LH Labcorp

company

SEC Filings & Insider Trading Activity 2026

Management Discussion & Analysis

• • Revenue $13,951.7 in FY2025, up 7.2% YoY from $13,008.9; driven by 4.4% organic growth, 2.5% acquisitions net of divestitures, 0.4% FX tailwind
• • Operating margin 9.9% vs 8.4% YoY; cost of revenues fell to 71.2% vs 72.1%; SG&A fell to 15.9% vs 17.1% of revenue
• • Best segment: Dx operating income $1,779.9 (+10.8% YoY), margin 16.4% vs 15.8%; BLS operating income $498.5 (+8.6%), margin 16.1% vs 15.7%
• • Operating cash flow $1,640.5 vs $1,585.8; capex $434.5 (3.1% of revenue); dividends $240.7; share repurchase authorization remaining $830.4
• • OBBBA legislation risk flagged — potential Medicaid/ACA coverage reduction; capex guided higher to ~4.0% of revenue in 2026; pending acquisitions (Empire City, Parkview) up to $415.0

Business Overview

• • Dual-segment lab services platform: Dx (clinical testing, $10.9B revenue) and BLS (drug development services, $3.1B revenue), total revenues $13.95B
• • New specialty test launches in 2025: Alzheimer's disease diagnostics, molecular residual disease detection, expanded oncology precision testing; also nationwide self-collection HPV/STI testing via Labcorp OnDemand
• • Strategic pivot toward health system partnerships (13 signed/completed in 2025) and international expansion via minority stake acquisition in SYNLAB, Europe's diagnostic services leader
• • BLS supported 85% of FDA-approved drugs/therapeutic products in 2025; $582M deployed in acquisitions; $450M in share buybacks at avg $254.17/share
• • Launched more than 130 new Dx tests in 2025 while expanding cell and gene therapy lab capacity in Madison, WI — targeting ~2,000 active global CGT clinical trials representing ~20% of biopharma pipelines

Risk Factors

• • Ravgen patent verdict: $272M jury award + $100M enhanced damages + $2.6M supplemental + $100/test ongoing royalty through patent life
• • PAMA Medicare reimbursement cuts frozen 2026, resuming 2027–2029 capped at 15%/year with further reductions possible thereafter
• • Senior notes $5.2B outstanding, $500M due within 12 months, plus $1.0B revolving credit facility with leverage ratio covenants
• • FDA's April 2024 LDT final rule rescinded after legal challenge, but potential reissuance could impose device-level regulatory burden on core lab testing
• • BLS dependent on specialized research animal supply; import restrictions or activist disruption could halt preclinical services with no short-term substitute

What are the latest LH SEC filings in 2026?

Labcorp (LH) has filed a 10-K annual report on February 24, 2026, a 10-Q quarterly report on May 4, 2026, an 8-K current report on July 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did LH file its most recent 10-K annual report?

Labcorp (LH) filed its most recent 10-K annual report on February 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view LH 10-Q quarterly reports?

Labcorp (LH)'s most recent 10-Q quarterly report was filed on May 4, 2026. SignalX displays every LH 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has LH filed recently?

Labcorp (LH)'s most recent 8-K was filed on July 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find LH insider trading activity (Form 4)?

SignalX aggregates every LH Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does LH file with the SEC?

Labcorp (LH) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new LH filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Labcorp (LH).

What is LH's SEC CIK number?

Labcorp (LH)'s SEC CIK (Central Index Key) number is 920148. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 920148 to look up all LH filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find LH return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Labcorp (LH) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.